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In their excellent and timely article ‘Patient
and public involvement in patient-reported out-
come measures: evolution not revolution,’[1] Sophie
Staniszewska and colleagues make important
points about the contribution of patients to the
development of patient-reported outcomemeasures
(PROMs), seeing ‘‘patients as research partners in
the research process, not just as those individuals
who are consulted or as subjects, fromwhom data
are sourced, to ensure the acceptability, relevance,
and quality of research.’’
As an advocate accustomed to collaborative
relationships with researchers, this seems self-
evident. And if any area of research design lends
itself to patient involvement, it is certainly PROMs!
1. A Different Kind of Expertise
Many researchers are still simply unfamiliar
with patients as collaborators, as opposed to re-
search participants – or ‘subjects,’ a term that is still
sometimes used. It’s not clear to these researchers
what role patients might play, or what value they
might add – that is, until they experience it for
themselves. It’s difficult to describe or quantify the
richness and dimension patient experiences can
bring to the table.
Inmy work as a research advocate, I often refer
to patients as ‘experts.’ With this characterization,
I hope to directly confront an objection we often
encounter, that patients do not have the requisite
understanding of the issues under study to allow
them to serve as research partners.
Before going further, I should point out that
by referring to patients as ‘experts,’ it is not my
intention to imply that they are the only experts
on a given research question, or that they know
better than professionals who conduct research
studies. What I do believe is that patients are, in
fact, experts when it comes to the subjective ex-
perience of their disease or condition, and that
they can bring values to the conversation that
may otherwise remain unaddressed. To the extent
that they are able to articulate their experiences,
and those of other patients with whom they share
that common bond, they can serve as effective
collaborators, adding to the quality of research
studies.
The characterization of patients as experts
questions an older paradigm in which knowledge
resides primarily within a hierarchy of trained
medical professionals, in which the patient’s role
is largely passive. From that mindset, concerns are
often raised about an advocate’s lack of medical
training, undue reliance on personal experiences,
failure to understand the scientific method, and
the like.
A more useful way to think about this might
be in terms of differing spheres of knowledge. It’s
my belief that a broader base of expertise, derived
from a variety of realms and perspectives, can
lead to much better research designs, tools and
outcomes. In the many committees and research
collaborations with which I’ve been involved over
20 years of advocacy, I’ve learned from academic
theorists, scientists, statisticians, physicians, epi-
demiologists, regulators, policymakers, and public
health experts, and I believe that they have
learned from me, in my role of offering a patient
perspective. At the very least, bringing patient
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voices into the conversation enlivens and deepens
any research discussion. Often, it can do much
more.
Since I work on behalf of women with meta-
static breast cancer, I am always acutely aware of
the importance of patient voices being heard.
Until very recently, the voices of women (and men)
suffering from the advanced form of the disease
that leads to almost all breast cancer deaths, almost
never broke the surface of the pink tide of breast
cancer awareness, with its emphasis on screening
and early detection. Wherever patient voices are
submerged, misunderstandings and myths pre-
vail. Without research to guide understanding,
the fears driving the avoidance persist. In such
under-researched conditions, patient perspectives
in the conduct and content of research are vital
if researchers – and society – are ever going to get
it right.
2. The Path of Advocacy
The path of healthcare advocacy usually be-
gins with a devastating illness or condition, our
own, or that of someone we love. Fear, grief, and
helplessness are transformed through learning
into action. As we become ‘experienced’ patients,
moving past our initial coping with diagnosis,
symptoms and treatments, many of us are moti-
vated to reach out to others who are coping with
our condition, to give back as we’ve been given to.
In an effort to make a broader impact, some of us
then begin a lengthy process of self-education so as
to understand the medical aspects of our disease
and science behind the condition and its treat-
ments more fully. If research becomes a partic-
ular interest, we then undertake training to learn
about scientific methodology and evidence-based
healthcare, research design, basic statistics, and
epidemiology.
What begins as difficult personal experience is
eventually transformed into an avocation and a
mission to be of help to others. Often, we discover
in our advocacy a chance to pursue undeveloped
interests and skills. But we always begin with the
authenticity of our own experience. It is our foun-
dation, although along the way we develop other
expertise that helps us participate more fully with
researchers. Of course, this occurs along a con-
tinuum of learning, where more seasoned advo-
cates can bring amore sophisticated understanding
to the research enterprise.
As we enter into the world of research, we may
risk losing touch with our roots – those raw per-
sonal experiences of patients struggling to cope
not only with their conditions, but with the
healthcare system and the choices they must
make. Resisting the impulse to become ‘junior’
doctors or scientists, we must constantly ground
ourselves in patient experience. For me, reading
and responding on a daily basis to women living
with metastatic breast cancer in online patient
communities offers that grounding.
In the US, where I live and work, patient and
research advocates have worked very hard to
form a bridge between the larger patient popu-
lation and the medical, research, and regulatory
establishment. We not only translate emerging
science for our constituents, but we also strive to
bring their concerns and voices back to the re-
search community.
3. Roles That Patients and Advocates
Can Play
In the case of PROMs, an advanced under-
standing of the theoretical constructs, design and
validation of PROMs instruments is hardly re-
quired. That is expertise that others bring to the
table. A motivated and vocal patient, especially
one who is in contact with other patients and
aware of the variety of experiences of disease and
its treatments, can be an excellent research part-
ner. Among the many issues such patients can
help to resolve are:
 do the PROMs fully capture patient experiences?
 is what really matters to patients being asked?
If not, what is missing?
 is there an important dimension of life or role
functioning that is not touched upon?
 are patients being asked what they actually
think and feel about their experiences, in the
context of their lives, beyond simply reporting
symptoms and side effects?
 is the language used clear and concise? Is
it specific enough? Are the words used simple
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and devoid of jargon? Can questions be easily
understood by patients with lower educational
levels? Are there good translations of the in-
strument for non-English-speaking patients?
 is the length of the PROM appropriate?
 does the timing and the setting for PROM
administration make sense for patients?
 are there built-in opportunities for feedback
from patients?
This is hardly a comprehensive list of questions,
of course, but I hope it clearly demonstrates some
areas of patient expertise. An iterative process
whereby an instrument is piloted with other
patients and revised accordingly will still be
important, but doesn’t obviate the need for col-
laboration with a patient or advocate. It seems
reasonable to think that good feedback through-
out the process of PROM development would
make the process of piloting and testing prior to
launch more efficient.
If a PROM is incorporated into a drug devel-
opment trial, and funded by a pharmaceutical
company, trained advocates who retain their in-
dependence of commercial interests will be able
to raise additional questions concerning whether
the PROMs being designed are sufficient to ad-
equately capture adverse effects of treatment. In
such cases, awareness of subtle framing and
wording of questions can be crucial so as not to
minimize the experience of treatment side effects,
an issue bound to become more problematic as
PROMs are fully integrated into drug develop-
ment. Although this has rarely been scrutinized,
as with every other member of a research group,
patients and advocates should be free of conflicts
of interest.
4. Measuring What Matters
When I became a research advocate, and was
first reading clinical trials results and attending
scientific meetings, it was like entering another
disturbing reality. This was an era when high-
dose chemotherapy with bone marrow trans-
plants still inspired hope. More was better. Two
and even three different chemotherapies at a time
were deemed superior, and dose ‘intensity’ was
the paradigm dominating treatment.
In those years, this approach was frequently
applied to metastatic breast cancer, a setting
where no drug, or combination of drugs, is cura-
tive, treatment is continuous, and being able to
live as well as possible for each remaining day is
crucial to women and their families. I knew di-
rectly from the women themselves how debilitat-
ing these drug combinations could be. For much
of their precious time they were simply too ill to
function, only recovering in time for the next
chemo cycle. Yes, the drugs sometimes appeared
to slow down disease progression a few weeks or
months – but at a heavy price of nausea, pain,
fevers, and crushing fatigue.
Yet when the results of these combined che-
motherapy trials were reported, I soon noticed,
even the grade 3 and 4 toxicities of these power-
ful drugs would typically be summarized in ab-
stracts as ‘expected,’ ‘manageable,’ and (my
personal favorite) ‘tolerable.’ To whom was this
tolerable? I wondered. How would they know
what patients actually felt if they didn’t ask?
Did tumor shrinkage really measure what mat-
tered to women, especially if extended survival
could not be proven? Was anyone asking patients
about their quality of life, and what mattered to
them?
Thankfully, in the years since, treatment has
come to favor sequential monotherapy, the ad-
ministration of one chemotherapy agent at a
time, and supportive care has improved sig-
nificantly. But I can’t help feeling that failing to
measure patient experiences contributed to the
suffering of that time.
The wider use of PROMs is a clear signal of a
new age of research where patient experience mat-
ters, and where the drug industry is being called
upon to demonstrate clinical benefit in mea-
surable ways that are meaningful to the patients
themselves. Involving patients and advocates in
the conduct of that research, and especially in the
design of the instruments that will measure pa-
tient experiences, is critical.
‘‘Compared with the progress made in [patient
and public involvement] in other areas of health
research,’’ writes Staniszewska et al., ‘‘there has been
little exploration of the potential for [patient and
public involvement] in contributing to enhanced
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quality, relevance, and acceptability of PROMs.’’
The time has come for this to change.
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